MARKET

CYCN

CYCN

Cyclerion Therapeutics Inc
NASDAQ
3.080
0.000
0.01%
Closed 16:00 03/27 EDT
OPEN
3.050
PREV CLOSE
3.080
HIGH
3.083
LOW
2.920
VOLUME
993
TURNOVER
0
52 WEEK HIGH
12.04
52 WEEK LOW
1.750
MARKET CAP
8.35M
P/E (TTM)
-1.3683
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CYCN last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at CYCN last week (0311-0315)?
Weekly Report · 03/18 11:57
Weekly Report: what happened at CYCN last week (0304-0308)?
Weekly Report · 03/11 11:52
Weekly Report: what happened at CYCN last week (0226-0301)?
Weekly Report · 03/04 11:56
Weekly Report: what happened at CYCN last week (0219-0223)?
Weekly Report · 02/26 12:13
Weekly Report: what happened at CYCN last week (0212-0216)?
Weekly Report · 02/19 12:16
Weekly Report: what happened at CYCN last week (0205-0209)?
Weekly Report · 02/12 12:02
12 Health Care Stocks Moving In Tuesday's Intraday Session
InVivo Therapeutics Hldg (NASDAQ:NVIV) stock rose 306.0% to $0.9 during Tuesday's regular session. The company's market cap increased to $2.7 million. Cyclerion Therapeutic stock rose 56.02% and Immunome stock increased by 26.06% in the same session. Losers include BioRestorative Therapies and Akso Health Group.
Benzinga · 02/06 17:31
More
About CYCN
Cyclerion Therapeutics, Inc. is a biopharmaceutical company. Its portfolio includes novel soluble guanylate cyclase (sGC) stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (CNS) and the periphery. Zagociguat is a clinical-stage CNS-penetrant sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY 3018 is a CNS-targeted sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. and being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases.

Webull offers Cyclerion Therapeutics Inc stock information, including NASDAQ: CYCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYCN stock methods without spending real money on the virtual paper trading platform.